The article discusses Sam Altman’s new biotech startup, Retro Biosciences, which aims to develop therapies to extend the human lifespan. Altman, the former president of Y Combinator, has invested $180 million of his own money into the company. Retro Biosciences is focused on reprogramming cells to reverse the aging process, with the goal of having a therapy ready for human trials by 2024. The company is taking a different approach from other longevity startups by targeting the fundamental biology of aging rather than specific age-related diseases. Altman believes that if successful, the therapies could add decades to the human lifespan. However, the article notes that the science behind reversing aging is still in its early stages and faces significant challenges. Retro Biosciences has assembled a team of top scientists and is using advanced technologies like machine learning to accelerate its research.
Source: https://www.businessinsider.com/retro-biosciences-sam-altman-longer-lifespan-2024-3